Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
Stephen K. Tahir(Abbott Fund), Christin Tse(Abbott Fund), Robert B. Warner(Abbott Fund), Shi‐Chung Ng(Ligand Pharmaceuticals (United States)), Susan E. Morgan-Lappe(Abbott Fund), Mark G. Anderson(Abbott Fund), Jun Chen(Abbott Fund), Aparna V. Sarthy(Abbott Fund), Xiufen Yang(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Saul H. Rosenberg(Abbott Fund), Steve W. Elmore(Abbott Fund)
Cited by 302
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k